Calyx announced it has been named an approved partner by ProTrials Research, Inc.
The partnership enables Calyx to extend its medical imaging, interactive response technology (IRT) and electronic data capture (EDC) solutions and services to help ProTrials' worldwide customers achieve their clinical development objectives. ProTrials' clients will leverage Calyx's technology to improve the reliability of clinical trial outcomes data.
Read more about this new partnership here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.